PCM
AXDX

Prelude Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Prelude Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,039
Closed -$750K – 1912
2019
Q3 		$750K Buy
4,039
+1,044
+35% +$202K 0.03% 422
2019
Q2 		$685K Buy
+2,995
New +$586K 0.03% 430
2018
Q1 		– Sell
-10
Closed -$3K – 1494
2017
Q4 		$3K Sell
10
-622
-98% -$146K ﹤0.01% 1289
2017
Q3 		$142K Sell
632
-21
-3% -$5.16K 0.01% 755
2017
Q2 		$179K Buy
+653
New +$177K 0.02% 611

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Prelude Capital Management's AXDX Position: Q4 2019 in Review

Prelude Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 4,039 shares — an estimated $750K sold.

Prelude Capital Management first reported a position in AXDX in Q2 2017 and held it in 5 quarters. The position peaked at $750K in Q3 2019. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

  • Prelude Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
  • Prelude Capital Management sold 4,039 Accelerate Diagnostics shares in Q4 2019, an estimated $750K.
  • Prelude Capital Management first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 5 quarters.
  • Prelude Capital Management's Accelerate Diagnostics position peaked at $750K in Q3 2019.
  • 109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.